Roche Reports registry Data for Daratumumab in Gastric cancer

Roche today announced registry results for daratumumab in patients with gastric cancer. The study demonstrated that daratumumab reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of gastric cancer and support the continued development of daratumumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.